Rothschild & Co Asset Management US’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Rothschild & Co Asset Management US’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-224,020	Closed	-$1.18M	–	586
2016 Q1	$1.18M	Buy	224,020 +7,688	+4%	+$47.1K	0.02%	312
2015 Q4	$1.7M	Buy	216,332 +37,145	+21%	+$320K	0.03%	319
2015 Q3	$1.51M	Sell	179,187 -185,012	-51%	-$1.71M	0.03%	314
2015 Q2	$3.99M	Buy	364,199 +8,008	+2%	+$103K	0.07%	280
2015 Q1	$4.98M	Buy	+356,191	New	+$5.45M	0.09%	268

Other funds holding INFI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rothschild & Co Asset Management US's INFI Position: Q2 2016 in Review

Rothschild & Co Asset Management US sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2016, closing a stake of 224,020 shares — an estimated $1.18M sold.

Rothschild & Co Asset Management US first reported a position in INFI in Q1 2015 and held it in 5 quarters. The position peaked at $4.98M in Q1 2015. 107 funds tracked by Wall St. Rank hold INFI as of Q2 2016.

Rothschild & Co Asset Management US reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Rothschild & Co Asset Management US sold 224,020 Infinity Pharmaceuticals, Inc. shares in Q2 2016, an estimated $1.18M.
Rothschild & Co Asset Management US first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
Rothschild & Co Asset Management US's Infinity Pharmaceuticals, Inc. position peaked at $4.98M in Q1 2015.
107 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2016.

Based on Rothschild & Co Asset Management US's 13F filing for Q2 2016, filed 3 Aug 2016.